Close X
Attorney Spotlight

Find out which two countries Cheryl Palmeri gets the most questions about related to International Trade in today's market? Find out more>


Close X


Search our Experience

Experience Spotlight

In June 2016, AmSurg Corp. and Envision Healthcare Holdings, Inc. (Envision) announced they have signed a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction. Upon completion of the merger, which is expected to be tax-free to the shareholders of both organizations, the combined company will be named Envision Healthcare Corporation and co-headquartered in Nashville, Tennessee and Greenwood Village, Colorado. The company's common stock is expected to trade on the New York Stock Exchange under the ticker symbol: EVHC. Bass, Berry & Sims served as lead counsel on the transaction, led by Jim Jenkins. Read more.

AmSurg logo

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Inside the FCA blogInside the FCA blog features ongoing updates related to the False Claims Act (FCA), including insight on the latest legal decisions, regulatory developments and FCA settlements. The blog provides timely updates for corporate boards, directors, compliance managers, general counsel and other parties interested in the organizational impact and legal developments stemming from issues potentially giving rise to FCA liability.

Read More >

Defense of Salix Pharmaceuticals in Product

Client Type: Public Company

We represented Salix Pharmaceuticals in cases in multiple jurisdictions alleging renal failure suffered as a result of using a pharmaceutical product. The plaintiffs allegedly suffered renal failure after using a cleansing product that is routinely prescribed prior to a colonoscopy procedure. We conducted the initial investigation into the company's new drug application, amended warnings, adverse event reports, and other pertinent documents.  We collected and preserved the pertinent documents through the use of a complimentary and secure extranet for the client.  We identified and interviewed the key company executives and employees involved in the issues that were pertinent to the litigation.  These cases focused on the adequacy of the warning labels that accompanied the product and alternative products that were less effective but arguably carried less risk to the patient. One case was dismissed after we deposed the plaintiff and obtained an admission during that deposition that she had just perjured herself after being confronted with a document that contradicted her testimony.  Other cases were successfully resolved.

Salix Pharmaceuticals, Inc. (NASDAQ: SLXP) is a specialist pharmaceutical company that develops drugs and medical devices to prevent and treat various gastrointestinal disorders.

You Also May Be Interested In:

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.